{
  "compound": "CBD",
  "condition": "DEPRESSION",
  "effect_size": "N/A (safety review)",
  "study_type": "SYSTEMATIC_REVIEW",
  "source": "NORML:DEPRESSION_SYSTEMATIC_REVIEW_003",
  "participants": "67 depression studies reviewed (N=4,218 total participants)",
  "year": 2021,
  "notes": "Cannabidiol Safety Profile in Depression: Comprehensive Systematic Review",
  "confidence": "medium",
  "abstract": "Excellent safety across all doses and durations; most common AEs: fatigue (8-14%), diarrhea (6-11%), appetite changes (5-9%); all mild-moderate"
}